Tirzepatide
Tirzepatide (GIP/GLP-1)
Reshape Your Confidence
Tirzepatide is the generic form of Mounjaro and Zepbound, both popular medications used for the management of type 2 diabetes and weight loss, respectively.
Tirzepatide is a dual-receptor agonist that binds two different receptors for greater weight-loss than semaglutide, which binds only one receptor. It is associated with fewer side effects than semaglutide and can be used as an alternative treatment for those with unsatisfactory results on semaglutide.
Tirzepatide (GIP/GLP-1)
Treatment Overview
Side effects are generally very mild and seldom result in a patient opting to stop treatment. Compared to semaglutide, tirzepatide has been associated with fewer side effects. The most common side effects are feelings of fullness, nausea, diarrhea, and constipation. Side effects typically dissipate within the first 2-3 weeks of treatment, but may temporarily return when the dose is increased.
Tirzepatide often results in greater weight loss than semaglutide with more tolerable side effects. While the rate of weight loss varies from patient to patient, it is exponentially faster in patients that incorporate the addition of diet and exercise modifications as directed by our providers.